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Serum Bile Acid Concentrations, Histopathological Features, and
Short-, and Long-term Survival in Horses with Hepatic Disease
B. Dunkel, S.A. Jones, M.J. Pinilla, and A.K. Foote
Background: Serum bile acid concentrations (SBA) and a histopathological biopsy score [Equine Vet J 35 (2003) 534] are
used prognostically in equine hepatic disease.
Hypothesis: Histopathologic features and scores, but not SBA, differ between survivors and nonsurvivors and correlate
with histopathologic evidence of hepatic inflammation and fibrosis.
Animals: Retrospective study. Records (1999–2011) of horses with hepatic disease diagnosed by biopsy and with concur-
rent measurements of SBA.
Methods: Retrospective cohort study. Biopsies were examined for inflammatory cell infiltration including type and distri-
bution, fibrosis, irreversible cytopathology affecting hepatocytes, hemosiderin, or other pigment deposition and bile duct pro-
liferation. SBA, histopathological findings and a histological score [Equine Vet J 35 (2003) 534] were compared between
short- (survival to discharge) and long-term (>6 months) survivors and correlations between SBA and histopathological find-
ings investigated.
Results: Of 81 cases 90% survived short-term and 83% long-term. Short-term and long-term nonsurvival were associated
with SBA (P = .009; P = .006), overall (P = .001; P = .002) and parenchymal (short-term only; P = .01) inflammation, portal
and bridging fibrosis (all P < .001), apoptosis or single cell necrosis (P < .001; P = .008), hemosiderin deposition in hepato-
cytes (P = .011; P = .028), biliary (both P < .001), vascular (P = .003; P = .045) and endothelial (P < .001; P = .02) hyper-
plasia, nucleic changes (P = .004; P < .001) and the histopathological score (both P < .001). SBA were significantly and
positively correlated with overall (P = .001), parenchymal (P < .001) and portal (P = .004) inflammation and portal
(P = .036) and bridging (P = .002) fibrosis.
Conclusions and Clinical Importance: SBA, histopathological findings and scores differ between survivors and nonsurvi-
vors. SBA concentrations are associated with inflammation and fibrosis suggesting interference with hepatic function. A
histopathological score >2 and, less so, SBA >20 lmol/L are specific but not sensitive indicators of nonsurvival.
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Currently, histopathologic examination of liver tissueis regarded by many clinicians as the most sensitive
method of diagnosing hepatic disease1,2 and histopatho-
logical findings from biopsied tissue in people correlate
well with subsequent gross postmortem findings.3 Histo-
pathology is also regarded as the best indicator of prog-
nosis in hepatic disease in horses and a scoring system
has been developed for this purpose.4 However, this
scoring system has not been evaluated in a different
case population. In the absence of a liver biopsy or for
continuous monitoring purposes, many clinicians anec-
dotally use serum bile acid concentrations (SBA) as a
surrogate prognostic indicator and concentrations
exceeding 20 lmol/L are predictive of nonsurvival.5
However, our clinical impression indicated that this
might not be uniformly applicable to all equine popula-
tions with hepatic disease. The prognostic value of SBA
relies on the fact that the detected loss of hepatic func-
tion is permanent or progressive or both. It is conceiv-
able that reversible changes, such as inflammatory
infiltration or reversible hepatocyte damage, could tem-
porarily interfere with hepatic function, leading to an
increase in SBA. With appropriate treatment or time,
the condition might resolve which would make SBA an
unreliable prognostic indicator. Furthermore, a large
number of horses in the early stages of liver disease
have SBA within the reference ranges6 and gaining
additional prognostic information from histopathologic
features would be useful. To date, few studies have
investigated the relationship between SBA and individ-
ual histopathologic features and short- and long-term
survival. As SBA are considered to be indicators of liver
function, a close association between SBA and histo-
pathological findings would be expected, particularly
between histological findings such as inflammation and
fibrosis, that could interfere with normal function.
The aim of the study was to determine whether SBA
and histologic variables including a histological score
were associated with short- (survival to discharge) and
long-term (>6 months after discharge) survival; differ-
ences between biochemical and hematological variables
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in short- and long-term survivors and nonsurvivors
were also evaluated. The study further assessed whether
SBA concentrations in horses with liver disease corre-
lated with histologic features. It was hypothesized that
histopathologic features and score, but not SBA, dif-
fered between survivors and nonsurvivors and that SBA
concentrations correlated with histopathologic evidence
of inflammation and fibrosis.
Materials and Methods
The study was carried out in accordance with the ethical guide-
lines of the participating institutions. In a retrospective study, all
horses presenting to two equine referral hospitals that had a liver
biopsy and concurrent ( 3 days) SBA measurement performed
between the years 1999 and 2011 were eligible for inclusion into
the study. The animal’s date of birth, age at biopsy, gender and
breed, SBA and, where available, other clinicopathological data
were recorded.
Archived formalin-fixed paraffin wax embedded trucut liver biopsy
samples were recut and 4 lm sections stained with haematoxylin &
eosin and van Gieson staining. To highlight fibrosis, deparaffinised
sections were stained for 7 minutes with Van Gieson stain (picric acid
and aqueous acid fuchsin, Leica Biosystems, Leica Microsystems
(UK), Ltd, Milton Keynes, Buckinghamshire, UK), dehydrated
through alcohol, cleared in xylene and mounted with DPX. All sam-
ples were reviewed and graded by two pathologists (MJP and AKF)
blinded to the outcome of the case. Only specimens with more than
6 lobules were scored. The portal tracts and hepatic parenchyma
were assessed for bile duct proliferation, fibrosis, irreversible
cytopathology affecting hepatocytes, hemosiderin or other pigment
deposition and inflammatory cell infiltration as detailed below.
The total length of the biopsies or where more than one slice
was available, the sum of the lengths was documented. Portal
numbers were counted and the degree of inflammatory infiltration
overall and separately within portals and parenchyma was scored
as absent, mild, moderate or severe. Inflammatory infiltrates were
graded as mild if up to 5 leucocytes were present within a portal
tract or lobule, moderate if 5–20 leucocytes were seen and severe if
more than 20 leucocytes were found.
Cell types within portal areas were counted and described based
on the following protocol: 0 = no inflammatory cells present,
1 = mononuclear cells present alone, 2 = neutrophilic with or
without mononuclear cell infiltrates and 3 = hemosiderophages
alone, or in combination with any other cell types. Cell types
within the parenchyma were also identified and described: 0 = no
inflammation, 1 = neutrophilic infiltration in the parenchyma and
also affecting portal areas, 2 = neutrophilic infiltration without
portal infiltrates and 3 = other cellular infiltrate.
Fibrosis was assessed and classified as absent, mild, moderate
or severe. Fibrosis was defined as mild where immature or mature
fibrous tissue expanded a portal tract up to twice the normal size,
moderate where a tract was 3 times the normal size and severe
where a tract was greater than or equal to 4 times the normal size
(often seen as bridging fibrosis across adjacent lobules). Bridging
fibrosis was also further graded as absent, mild (delicate fibrosis
confined to portal-portal distribution), moderate (extensive fibrosis
but still predominantly confined to portal-portal regions) or severe
(extensive fibrosis, extending across the portal plate, with disrup-
tion of the normal lobular pattern).
Apoptosis or single cell necrosis or both were graded as absent,
mild (less than 2 cell per lobule), moderate (2–5 cells per lobule) or
severe (>5 cells per lobule, often also including some individual cell
necrosis).
Distribution of hemosiderin was assessed within 3 regions:
within Kupffer cells, portal areas and hepatocytes. Presence of
hemosiderin was recorded as absent, mild (fewer than 25% of cells
affected), moderate (25–50% of cells affected) and severe (>50% of
cells affected).
Bile duct proliferation, vascular hyperplasia and hyperplasia of
the sinusoidal endothelium (endothelial hyperplasia) were graded
according to the number of biliary branches/number of blood
vessels/hyperplastic sections in portal tracts sectioned in a typical
portal triad as absent or mild containing 2–3, moderate containing
4–6 and severe containing greater than 7 biliary branches/vessels/
sections.
Bile stasis (canalicular and ductal) was assessed as absent or
present.
Cytoplasmic swelling was also assessed and scored as absent,
mild (approximately 1.59 normal diameter), moderate (approxi-
mately 29 normal diameter) or severe (≥39 normal diameter).
The swelling distribution was then further classified as absent,
affecting hepatocytes closest to arterial and portal inflow, within
the transitional zone, periacinar (comprising the hepatocytes near-
est to the outflow; terminal hepatic venule), or combinations of
the above.
Changes to hepatocyte nuclei (nucleic changes) were scored as
absent (no significant anisokaryosis), mild (mild anisokaryosis
without megalocytosis), moderate (moderate anisokaryosis  occa-
sional megalocytosis) and severe (frequent megalocytosis >1 per
lobule).
A histological score was assigned.4
Records were reviewed to determine if animals were known to
have died, either before discharge or subsequently. Owners or the
referring veterinary surgeons of horses that were not known to be
dead were contacted at least 6 months after discharge to determine
survival outcome. Where applicable, the date and cause of death
was ascertained. Survival was categorised as short- (survival to dis-
charge) and long-term survival (survival to at least 6 months after
discharge).
Statistical analysis
Continuous data are summarized as mean  standard deviation
(normally distributed), median (range) (not normally distributed)
and categorical data as number and percentage. Normality of the
data was assessed using a Shapiro-Wilk test. Differences in SBA,
histological features and scores and biochemical and hematologic
variables between short- and long-term survivors and nonsurvivors
were explored using a Student’s t-test (normally distributed contin-
uous data) or Mann-Whitney U-test (not normally distributed con-
tinuous data) and chi-square or Fisher’s exact test (categorical
data), respectively. The correlation between log transformed SBA
and histological features was explored using univariate analysis of
variance. Receiver-operator curves were generated to determine
optimal cut-off points for SBA as indicator for short- and long-
term nonsurvival and histopathology scores as indicators for
short- and long-term nonsurvival. Sensitivity and specificity were
reported. In addition, the previously suggested cut-off point of
>20 lmol/L was explored in the same manner. The area under the
curve (AUC) was also determined. All statistical analyses were
performed using a commercially available software programa ;
significance was set at P ≤ .05.
Results
Eighty-one horses fulfilled the inclusion criteria for
the study, 36 from hospital 1 and 45 from hospital 2;
24 horses (30%) were female and 57 (70%) were male
with a mean age of 11  5.4 years. Two horses from
hospital 1 had biopsies performed before June 2001 and
might have been included in an earlier study.4 Eight
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(10%) horses died or were euthanized before discharge
from the hospital whilst 6 (7%) animals were eutha-
nized or died within 6 months of discharge, all for rea-
sons pertaining directly to liver disease. Sixty-seven
animals (83%) survived long-term and 14 (17%) did
not.
The mean biopsy length was 18.4  7.8 mm and was
not different between short-term survivors and nonsur-
vivors (18.5  7.9 mm versus 16.8  8.2 mm; P = .58)
and long-term survivors and nonsurvivors
(18.2  7.8 mm versus 18.9  8.6 mm; P = .76). SBA,
overall and parenchymal (short-term survival only)
inflammation, portal and bridging fibrosis, apoptosis or
single cell necrosis, or both hemosiderin deposition in
hepatocytes, biliary and vascular hyperplasia, endothe-
lial hyperplasia, nucleic changes, and the histopathology
score were significantly different between survivors and
nonsurvivors (Tables 1–3). Comparison of biochemical
and hematologic variables between short- and long-term
survivors and nonsurvivors are shown in Table 1.
SBA were significantly and positively correlated with
overall, parenchymal and portal inflammation, portal
and bridging fibrosis, hemosiderin deposition in Kupffer
cells, nucleic changes and the histological score
(Table 4).
The AUC for SBA was 0.78 (95% confidence interval
[CI]: 0.66–0.91; P = .009) for short-term survival and
0.8 (95% CI: 0.6–1.0; P = .005) for long-term survival.
The AUC for the histological score was 0.74 (95% CI:
0.56–0.89; P = .006) as indicator for short-term survival
and 0.85 (95% CI: 0.7–0.99; P < .001) as indicator for
long-term nonsurvival. The optimal cut off points for
short- and long-term nonsurvival were SBA ≥17 lmol/L
and a histology score >3 and ≥16 lmol/L and a histo-
logical score >2, respectively. Sensitivity and specificity
are reported in Table 5.
No long-term survivor had a score >3. However,
29% (n = 4) of horses that did not survive >6 months
had a score of 0 or 1 and SBA concentrations of 2 of
these (14%) were also within the reference range
(<12.8 lmol/L).
Discussion
In agreement with other studies SBA concentrations
were higher in short- and long-term nonsurvivors than
short- and long-term survivors.5,7 However, the clinical
impression that high SBA were not necessarily associ-
ated with nonsurvival in the examined population was
supported by the relatively low specificity of two cut-off
points (one determined in the study and the previously
reported cut-off of ≥20 lmo/L).
The diagnostic value of SBA in people is undisputed
as an increase in the serum is a highly specific for hepa-
tic disease, although only moderately sensitive. In cases
of liver cirrhosis in people SBA have long-term prog-
nostic value8,9 while in cases of acute hepatitis, clinical
improvement is often paralleled by decreasing SBA, cor-
responding with normalizing hepatic function.10,11 In
these instances, one time measurements of SBA would
not be useful prognostic indicators.
In horses, classically described hepatic diseases such
as serum hepatitis, cholangioheptitis, neoplasia, Clos-
tridium piliformis infection, and pyrrolizidine alkaloid
toxicity are all associated with severe or irreversible
liver damage, or both, and a high case fatality, often
ranging from 50 to 100%.7,12,13 In many of these cases,
loss of hepatic function is expected to be permanent or
progressive, or both, and SBA are likely to be indicative
of extend of the irreparable damage and therefore also
of the prognosis. In these cases, a close association
between SBA, presence and severity of hepatic damage
and a negative outcome would be expected. Similar to
the findings in people, SBA would be expected to corre-
late with irreversible hepatic changes. In this study, a
correlation between SBA and portal and bridging fibro-
sis as well as nucleic changes, which are considered to
be irreversible, was demonstrated and those histological
features were also more commonly observed in nonsur-
vivors.
However, SBA returned to normal limits in horses
that survived hepatic necrosis which presumably corre-
sponded to improved hepatic function as regeneration
ensued.14 The horses examined here experienced pre-
dominately mild-to-moderate hepatic disease of
unknown etiology and in these cases SBA might be
more indicative of a temporary and potentially revers-
ible compromise of hepatic function. This assumption is
supported by the low specificity of SBA >17 and
>20 lmol/L for nonsurvival and the finding of signifi-
cant correlation between SBA and potentially reversible
histological findings such as inflammation and hemosid-
erin accumulation in Kupffer cells. However, overall
and parenchymal (short-term survival only), but not
portal, inflammation was also more common in nonsur-
vivors and although the inflammation may be revers-
ible, it could equally be progressive. Enhanced
prognostic information could therefore probably be
gained from serial SBA monitoring.14
The histological score performed well as a specific
albeit only moderately sensitive indicator of short- and
long-term nonsurvival.4 Based on the high specificity
the histological score provided the best prognostic
information for long-term survival and was numerically
superior to SBA for short- and long-term survival. A
limitation of the study is that the score was developed
in the same geographic location (South-East England)
in which this study was performed and it is likely that
the nature of hepatic disease was very similar in the
horses used to develop the score to the horses investi-
gated here. Results might not be directly transferrable
to areas with very different disease types and re-evalua-
tion of the scoring system is therefore advisable before
it is used for prognostic purposes in different areas.
Furthermore, all horses with hepatic disease were analy-
sed together, irrespective of the underlying etiology and
results might be different for certain subpopulations.
The scoring system was designed for diffuse, non-neo-
plastic hepatopathies and most cases described here
would have fallen into this category.4 Lastly, outcome
could have been influenced by the initiation of adequate
treatment, or lack thereof. All nonsurvivors in the study
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were euthanized because of progression of hepatic dis-
ease, despite administration of treatment, and no ani-
mal was euthanized because of financial limitations.
In the addition to the histological features evaluated in
the previous study,4 other histologic aspects of hepatic
disease were included that, to the authors’ knowledge,
have not been investigated previously. Endothelial
hyperplasia, a feature in people referred to as capillar-
ization of the sinusoidal endothelium, is defined as the
loss of the characteristic fenestrated phenotype of the
endothelial cells with formation of an organized base-
ment membrane. Capillarization precedes fibrosis in
people and experimental animals and it has been
suggested that capillarization might even initiates the
Table 1. Comparison of biochemical and haematological variables between short- (survival to discharge) and long-
term (survival >6 months after discharge) survivors and nonsurvivors.
Short-term
Survivor
Short-term
Nonsurvivor P-value
Long-term
Survivor
Long-term
Nonsurvivor
(All Nonsurvivorsa) P-value
Serum bile acids (lmol/L) 12.5 (1.5–82.5)
n = 73
28.1* (11.9–42.8)
n = 8
.009 12.3 (1.5–82.5)
n = 67
28.1* (6.3–45.2)
n = 14
.006
Total plasma protein (g/dL) 6.5  0.6
n = 68
7.5  1.1*
n = 6
.001 6.5  0.58
n = 62
6.9  1.0
n = 12
.094
Albumin (g/dL) 3.5  0.41
n = 69
2.8  0.71*
n = 6
.003 3.5  0.38
n = 63
2.9  0.48*
n = 12
<.001
Globulin concentration (g/dL) 3.0 (1.8–4.4)
n = 68
4.2* (4.0–7.2)
n = 6
<.001 3.0 (1.8–4.1)
n = 62
4.0* (2.1–7.2)
n = 12
.001
Fibrinogen (mg/dL) 280 (100–950)
n = 57
690* (180–730)
n = 5
.025 270 (100–510)
n = 52
590* (100–950)
n = 10
.019
AST (IU/L) 530 (227–2520)
n = 72
482 (159–651)
n = 5
.26 547 (227–2520)
n = 66
436 (159–762)
n = 11
.091
Creatine kinase (IU/L) 300 (86–2180)
n = 64
336 (179–2889)
n = 5
.43 306 (86–2180)
n = 58
277 (179–2889)
n = 11
.84
LDH (IU/L) 730  305
n = 30
393  379
n = 3
.13 641 (318–1614)
n = 29
279* (171–831)
n = 4
.041
Sorbitol dehydrogenase (IU/L) 16 (1.9–209)
n = 36
181 (25–328)
n = 3
.051 17 (1.9–209)
n = 31
22 (8.5–328)
n = 8
.59
Gamma-glutamyltransferase (IU/L) 130 (14–1587)
n = 73
121 (49–185)
n = 3
.56 136 (14–1587)
n = 67
90 (42–300)
n = 9
.24
GLDH (IU/L) 7.9 (1.2–5704)
n = 31
11 (9–12.7)
n = 2
.85 7.2 (1.2–5704)
n = 30
12.7 (9.2–15.3)
n = 3
.68
Urea (mg/dL) 14.3 (6.4–22.4)
n = 49
16 (10.1–56.9)
n = 5
.32 14.6 (9.8–22.4)
n = 45
13.7 (6.4–56.9)
n = 9
.51
Creatinine (mg/dL) 1.3 (0.9–2.1)
n = 62
1.2 (1.1–4.4)
n = 5
.21 1.4 (0.9–2.1)
n = 56
1.2 (1.1–4.4)
n = 11
.1
Serum amyloid A (mg/L) 0 (0–249)
n = 38
147* (0.6–990)
n = 4
<.001 0 (0–67.3)
n = 36
147* (0.6–990)
n = 6
<.001
Total bilirubin (mg/dL) 1.5 (0.4–12.3)
n = 57
4.4* (2.5–6.1)
n = 3
.023 1.4 (0.4–12.3)
n = 51
2.5* (0.9–6.1)
n = 9
.027
Direct bilirubin (mg/dL) 0.25  0.09
n = 20
0.4
n = 1
0.2 (0.1–0.4)
n = 19
0.2 and 0.4
n = 2
.4
Indirect bilirubin (mg/dL) 1.2 (0.2–6.8)
n = 20
5.9
n = 1
1.2 (0.2–6.8)
n = 19
1.5 and 5.9
n = 2
.23
Triglycerides (mg/dL) 41 (15–743)
n = 8
1496 (32–3186)
n = 3
.15 41 (15–743)
n = 8
1496 (15–3186)
n = 3
.15
Red blood cell count (9106/lL) 7.9 (4.7–11.8)
n = 31
10.0 (7.8–17.8)
n = 4
.097 8.0 (4.7–11.8)
n = 29
8.5 (5.2–17.8)
n = 5
.45
Hemoglobin (g/dL) 13.2 (8.9–17.2)
n = 31
11.5 (7.6–16.4)
n = 4
.64 13.3 (9.9–17.2)
n = 30
8.9 (7.6–16.4)
n = 5
.26
Leukocyte count (9103/lL) 7.5 (3.3–18.1)
n = 60
8.1 (4.2–14.3)
n = 5
.52 7.3 (3.3–18.1)
n = 54
8.1 (4.2–16.4)
n = 11
.077
Neutrophil count (9103/lL) 4.2 (1.4–14.9)
n = 59
7.0 (1.2–11.5)
n = 4
.32 4.1 (1.4–14.8)
n = 53
7.0* (1.2–13.3)
n = 10
.042
Lymphocyte count (9103/lL) 2.5  0.9
n = 59
2.3  0.7
n = 4
.71 2.5  0.9
n = 53
2.7 (1.1–4.6)
n = 10
.55
aLong-term nonsurvivors include all short- and long-term nonsurvivors.
*P ≤ .05.
AST, aspartate aminotransferase; LDH, lactate dehydrogenase; GLDH, glutamate dehydrogenase; statistical significance was set at
P ≤ .05.
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process.15 Interestingly, endothelial hyperplasia was sig-
nificantly associated with short- and long-term survival
in this study but further investigations are required to
investigate the importance and implications of this his-
tological finding.
Similar to other studies5,7,14 significant differences in
haematological and biochemical data between survi-
vors and nonsurvivors were established. As previously
reported,5 low albumin and high globulin concentra-
tions were associated with short- and long-term non-
survival. Low albumin concentrations are an
infrequent finding in hepatic disease in horses.16 The
presence of hypoalbuminemia in combination with hy-
perglobulinemia might therefore be particularly rele-
vant when trying to establish a prognosis. The finding
of lower LDH activities in nonsurvivors was unex-
pected and is difficult to explain. LDH is not a liver-
specific enzyme and it is possible that muscle damage
Table 2. Comparison of histopathological findings between short- (survival to discharge; A) and long-term (survival
>6 months after discharge; B) survivors and nonsurvivors.
(A)
Short-term Survivor
(n = 73) (% Horses)
Short-term Nonsurvivor
(n = 8) (% Horses)
P-valueAbsent Mild Moderate Severe Absent Mild Moderate Severe
Inflammation* 4 63 32 1 0 50 25 25 .009
Portal inflammation 6 63 27 4 13 50 13 25 .09
Parenchymal inflammation* 40 44 15 1 25 38 13 25 .01
Portal fibrosis* 13 67 8 3 13 0 63 25 <.001
Bridging fibrosis* 59 36 6 0 13 25 50 13 <.001
Apoptosis, single cell necrosis, or both* 70 26 3 0 50 25 0 25 <.001
Hemosiderin (portal) 48 37 14 1 38 38 13 13 .29
Hemosiderin (Kupffer cells) 44 48 7 1 38 38 13 13 .24
Hemosiderin (hepatocytes)* 73 21 7 0 75 0 13 13 .011
Biliary hyperplasia* 71 25 4 0 38 38 0 25 <.001
Vascular hyperplasia* 61 37 1 0 50 25 25 0 .003
Bile stasis 100 0 0 0 88 13 0 0 .099
Endothelial hyperplasia* 78 22 0 0 25 63 13 0 <.001
Cytoplasmatic swelling 27 55 18 1 38 50 13 0 .9
Distribution of cytopl swellb .9
Nucleic changes* 49 49 1 0 38 38 25 0 .004
0 1 2 3 0 1 2 3
Portal cell types 6 41 18 34 12.3 25 13 50 .65
Parenchymal cell types 40 27 23 10 25 38 13 25 .46
(B)
Long-term Survivor
(n = 67) (% Horses)
Long-term Nonsurvivor (All
Nonsurvivorsa; n = 14) (% Horses)
P-valueAbsent Mild Moderate Severe Absent Mild Moderate Severe
Inflammation* 5 64 31 0 0 50 29 21 .002
Portal inflammation 6 64 27 3 7 50 21 21 .075
Parenchymal inflammation 40 45 13 2 29 36 21 14 .1
Portal fibrosis* 22 73 5 0 14 0 57 29 <.001
Bridging fibrosis* 61 36 3 0 21 29 43 7 <.001
Apoptosis, single cell necrosis or both* 72 25 2 0 50 29 7 14 .008
Hemosiderin (portal) 51 37 10 2 29 36 29 7 .14
Hemosiderin (Kupffer cells) 45 46 8 2 36 50 7 7 .63
Hemosiderin (hepatocytes)* 72 22 6 0 79 0 14 7 .028
Biliary hyperplasia* 75 24 2 0 36 36 14 14 <.001
Vascular hyperplasia* 64 34 2 0 43 43 14 0 .045
Bile stasis 100 0 0 0 93 7 0 0 .173
Endothelial hyperplasia* 78 22 0 0 50 43 7 0 .02
Cytoplasmatic swelling 30 54 16 0 21 57 14 7 .16
Distribution of cytopl swellb .75
Nucleic changes* 52 48 0 0 29 50 21 0 <.001
0 1 2 3 0 1 2 3
Portal cell types 6 42 15 36 7 29 29 36 .62
Parenchymal cell types 40 25 25 9 29 43 7 21 .17
aLong-term nonsurvivors include all short- and long-term nonsurvivors.
bCytoplasmatic swelling was assessed in 5 distribution patterns, a detailed description of the grading criteria used is given in the text and
only the P-value is displayed.
*P ≤ .05; statistical significance was set at P ≤ .05.
Different inflammatory cell infiltrates are displayed in bold text.
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in survivors in association with the low number of
nonsurvivors in which the test was performed has
contributed to the finding of this counterintuitive sta-
tistical difference although differences in creatine
kinase (CK) might have been expected if muscle dam-
age was involved. Plasma fibrinogen concentrations
are higher in nonsurviving horses with hepatic disease
and it is possible that long-standing inflammatory
processes in the liver ultimately lead to liver failure
and death.5 No specific inflammatory cell type was
associated with nonsurvival. While parenchymal and
portal inflammation correlate with SBA and therefore
might negatively influence liver function only paren-
chymal inflammation was associated with short-term
survival. This could suggest that parenchymal inflam-
mation is more likely to contribute to or trigger
events that lead to hepatic failure and nonsurvival.
Further large scale investigation into the different dis-
tributions and also types of inflammatory infiltrates
are clearly needed.
In summary, SBA, some histopathological findings
and histopathological scores differed between survivors
and nonsurvivors. SBA concentrations are associated
with inflammation and fibrosis suggesting that both
interfere with hepatic function. A histopathological
score >2 and, to a lesser degree, SBA >20 lmol/L are
specific but not sensitive indicators of nonsurvival. For
the population examined the histological score offered
the best specificity for long-term survival.
Footnote
a IBM SPSS statistics 19, P.O. Box 41, North Harbour Ports-
mouth, Hampshire PO6 3AU, UK
Acknowledgments
Conflict of Interest Declaration: Authors disclose no
conflict of interest.
Table 3. Comparison of histological score as described by Durham et al. (2003) between short- (survival to dis-
charge; A) and long-term (survival >6 months after discharge; B) survivors and nonsurvivors.
(A) Short Term Survivor (n = 73) Short-term Nonsurvivor (n = 8)
P-
value
Histological
score
0 1 2 3 4 5 0 1 4 8 14
52 (71%) 12 (16%) 2 (3%) 5 (7%) 1 (1%) 1 (1%) 2 (25%) 1 (13%) 3 (38%) 1 (13%) 1 (13%) <.001
(B) Long-term Survivor (n = 67) Long-term Nonsurvivor (All Nonsurvivorsa; n = 14)
P-
value
Histological
score
0 1 2 3 0 1 2 3 4 5 8 14
51 (78%) 12 (18%) 1 (2%) 3 (5%) 3 (21%) 1 (7%) 1 (7%) 2 (14%) 4 (29%) 1 (7%) 1 (7%) 1 (7%) <.001
aLong-term nonsurvivors include all short- and long-term nonsurvivors.
*P ≤ .05; statistical significance was set at P ≤ .05.
Table 4. Correlation between log transformed serum
bile acid concentrations and histological features and
scores.
Regression
Coefficient  SEM
P-
value
Inflammation* 0.18  0.051 .001
Portal inflammation* 0.141  0.047 .004
Parenchymal inflammation* 0.155  0.038 <.001
Portal fibrosis* 0.095  0.045 .036
Bridging fibrosis* 0.141  0.044 .002
Apoptosis and/or single cell necrosis 0.085  0.051 .099
Hemosiderin (portal) 0.083  0.042 .051
Hemosiderin (Kupffer cells)* 0.104  0.046 .026
Hemosiderin (hepatocytes) 0.053  0.05 .291
Biliary hyperplasia 0.094  0.049 .056
Vascular hyperplasia 0.056  0.06 .347
Bile stasis 0.078  0.306 .8
Endothelial hyperplasia 0.068  0.07 .33
Cytoplasmatic swelling 0.01  0.049 .85
Distribution of cytopl swell 0.004  0.011 .69
Nuclei* 0.199  0.055 .001
Histological score* 0.05  0.015 .002
*P ≤ .05.
Distribution of cytopl. swell: distribution of cytoplasmatic swell-
ing; SEM: standard error of the mean; statistical significance was
set at P ≤ .05.
Table 5. Sensitivity and specificity of different cut-off
points for serum bile acid concentrations (SBA) and
histological score as indicators of nonsurvival.
Short-term Nonsurvival Sensitivity (%) Specificity (%)
SBA ≥17 lmo/L 75 70
SBA ≥20 lmo/L 62.5 78.1
Histological score >2 62.5 90.4
Histological score >3 62.5 97.3
Long-term nonsurvival (all nonsurvivorsa)
SBA ≥16 lmo/L 78.6 65.7
SBA ≥20 lmo/L 57.1 80.6
Histological score >2 64.3 95.5
Histological score >3 50 100
aLong-term nonsurvivors include all short- and long-term non-
survivors.
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